Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease

You Me Sung, Taehee Lee, Hyejin Yoon, Amanda Marie DiBattista, Jung Min Song, Yoojin Sohn, Emily Isabella Moffat, R. Scott Turner, Mira Jung, Jungsu Kim, Hyang Sook Hoe

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Histone deacetylase inhibitors (HDACIs) alter gene expression epigenetically by interfering with the normal functions of HDAC. Given their ability to decrease Aβ levels, HDACIs are a potential treatment for Alzheimer's disease (AD). However, it is unclear how HDACIs alter Aβ levels. We developed two novel HDAC inhibitors with improved pharmacological properties, such as a longer half-life and greater penetration of the blood-brain barrier: mercaptoacetamide-based class II HDACI (coded as W2) and hydroxamide-based class I and IIHDACI (coded as I2) and investigated how they affect Aβ levels and cognition. HDACI W2 decreased Aβ40 and Aβ42 in vitro. HDACI I2 also decreased Aβ40, but not Aβ42. We systematically examined the molecular mechanisms by which HDACIs W2 and I2 can decrease Aβ levels. HDACI W2 decreased gene expression of γ-secretase components and increased the Aβ degradation enzyme Mmp2. Similarly, HDACI I2 decreased expression of β- and γ-secretase components and increased mRNA levels of Aβ degradation enzymes. HDACI W2 also significantly decreased Aβ levels and rescued learning and memory deficits in aged hAPP 3xTg AD mice. Furthermore, we found that the novel HDACI W2 decreased tau phosphorylation at Thr181, an effect previously unknown for HDACIs. Collectively, these data suggest that class II HDACls may serve as a novel therapeutic strategy for AD.

Original languageEnglish (US)
Pages (from-to)192-201
Number of pages10
JournalExperimental Neurology
Volume239
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Alzheimer Disease
Learning
Amyloid Precursor Protein Secretases
Gene Expression
Aptitude
Memory Disorders
Enzymes
Blood-Brain Barrier
Cognition
Half-Life

Keywords

  • AD
  • Alzheimer's disease
  • Amyloid precursor protein
  • Amyloid-β
  • APP
  • Epigenetics
  • HDACI
  • Histone deacetylase inhibitors

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease. / Sung, You Me; Lee, Taehee; Yoon, Hyejin; DiBattista, Amanda Marie; Song, Jung Min; Sohn, Yoojin; Moffat, Emily Isabella; Turner, R. Scott; Jung, Mira; Kim, Jungsu; Hoe, Hyang Sook.

In: Experimental Neurology, Vol. 239, No. 1, 01.2013, p. 192-201.

Research output: Contribution to journalArticle

Sung, YM, Lee, T, Yoon, H, DiBattista, AM, Song, JM, Sohn, Y, Moffat, EI, Turner, RS, Jung, M, Kim, J & Hoe, HS 2013, 'Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease', Experimental Neurology, vol. 239, no. 1, pp. 192-201. https://doi.org/10.1016/j.expneurol.2012.10.005
Sung, You Me ; Lee, Taehee ; Yoon, Hyejin ; DiBattista, Amanda Marie ; Song, Jung Min ; Sohn, Yoojin ; Moffat, Emily Isabella ; Turner, R. Scott ; Jung, Mira ; Kim, Jungsu ; Hoe, Hyang Sook. / Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease. In: Experimental Neurology. 2013 ; Vol. 239, No. 1. pp. 192-201.
@article{798225295c0c4dafb8142b43cc6f2071,
title = "Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease",
abstract = "Histone deacetylase inhibitors (HDACIs) alter gene expression epigenetically by interfering with the normal functions of HDAC. Given their ability to decrease Aβ levels, HDACIs are a potential treatment for Alzheimer's disease (AD). However, it is unclear how HDACIs alter Aβ levels. We developed two novel HDAC inhibitors with improved pharmacological properties, such as a longer half-life and greater penetration of the blood-brain barrier: mercaptoacetamide-based class II HDACI (coded as W2) and hydroxamide-based class I and IIHDACI (coded as I2) and investigated how they affect Aβ levels and cognition. HDACI W2 decreased Aβ40 and Aβ42 in vitro. HDACI I2 also decreased Aβ40, but not Aβ42. We systematically examined the molecular mechanisms by which HDACIs W2 and I2 can decrease Aβ levels. HDACI W2 decreased gene expression of γ-secretase components and increased the Aβ degradation enzyme Mmp2. Similarly, HDACI I2 decreased expression of β- and γ-secretase components and increased mRNA levels of Aβ degradation enzymes. HDACI W2 also significantly decreased Aβ levels and rescued learning and memory deficits in aged hAPP 3xTg AD mice. Furthermore, we found that the novel HDACI W2 decreased tau phosphorylation at Thr181, an effect previously unknown for HDACIs. Collectively, these data suggest that class II HDACls may serve as a novel therapeutic strategy for AD.",
keywords = "Aβ, AD, Alzheimer's disease, Amyloid precursor protein, Amyloid-β, APP, Epigenetics, HDACI, Histone deacetylase inhibitors",
author = "Sung, {You Me} and Taehee Lee and Hyejin Yoon and DiBattista, {Amanda Marie} and Song, {Jung Min} and Yoojin Sohn and Moffat, {Emily Isabella} and Turner, {R. Scott} and Mira Jung and Jungsu Kim and Hoe, {Hyang Sook}",
year = "2013",
month = "1",
doi = "10.1016/j.expneurol.2012.10.005",
language = "English (US)",
volume = "239",
pages = "192--201",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease

AU - Sung, You Me

AU - Lee, Taehee

AU - Yoon, Hyejin

AU - DiBattista, Amanda Marie

AU - Song, Jung Min

AU - Sohn, Yoojin

AU - Moffat, Emily Isabella

AU - Turner, R. Scott

AU - Jung, Mira

AU - Kim, Jungsu

AU - Hoe, Hyang Sook

PY - 2013/1

Y1 - 2013/1

N2 - Histone deacetylase inhibitors (HDACIs) alter gene expression epigenetically by interfering with the normal functions of HDAC. Given their ability to decrease Aβ levels, HDACIs are a potential treatment for Alzheimer's disease (AD). However, it is unclear how HDACIs alter Aβ levels. We developed two novel HDAC inhibitors with improved pharmacological properties, such as a longer half-life and greater penetration of the blood-brain barrier: mercaptoacetamide-based class II HDACI (coded as W2) and hydroxamide-based class I and IIHDACI (coded as I2) and investigated how they affect Aβ levels and cognition. HDACI W2 decreased Aβ40 and Aβ42 in vitro. HDACI I2 also decreased Aβ40, but not Aβ42. We systematically examined the molecular mechanisms by which HDACIs W2 and I2 can decrease Aβ levels. HDACI W2 decreased gene expression of γ-secretase components and increased the Aβ degradation enzyme Mmp2. Similarly, HDACI I2 decreased expression of β- and γ-secretase components and increased mRNA levels of Aβ degradation enzymes. HDACI W2 also significantly decreased Aβ levels and rescued learning and memory deficits in aged hAPP 3xTg AD mice. Furthermore, we found that the novel HDACI W2 decreased tau phosphorylation at Thr181, an effect previously unknown for HDACIs. Collectively, these data suggest that class II HDACls may serve as a novel therapeutic strategy for AD.

AB - Histone deacetylase inhibitors (HDACIs) alter gene expression epigenetically by interfering with the normal functions of HDAC. Given their ability to decrease Aβ levels, HDACIs are a potential treatment for Alzheimer's disease (AD). However, it is unclear how HDACIs alter Aβ levels. We developed two novel HDAC inhibitors with improved pharmacological properties, such as a longer half-life and greater penetration of the blood-brain barrier: mercaptoacetamide-based class II HDACI (coded as W2) and hydroxamide-based class I and IIHDACI (coded as I2) and investigated how they affect Aβ levels and cognition. HDACI W2 decreased Aβ40 and Aβ42 in vitro. HDACI I2 also decreased Aβ40, but not Aβ42. We systematically examined the molecular mechanisms by which HDACIs W2 and I2 can decrease Aβ levels. HDACI W2 decreased gene expression of γ-secretase components and increased the Aβ degradation enzyme Mmp2. Similarly, HDACI I2 decreased expression of β- and γ-secretase components and increased mRNA levels of Aβ degradation enzymes. HDACI W2 also significantly decreased Aβ levels and rescued learning and memory deficits in aged hAPP 3xTg AD mice. Furthermore, we found that the novel HDACI W2 decreased tau phosphorylation at Thr181, an effect previously unknown for HDACIs. Collectively, these data suggest that class II HDACls may serve as a novel therapeutic strategy for AD.

KW - Aβ

KW - AD

KW - Alzheimer's disease

KW - Amyloid precursor protein

KW - Amyloid-β

KW - APP

KW - Epigenetics

KW - HDACI

KW - Histone deacetylase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84868549261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868549261&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2012.10.005

DO - 10.1016/j.expneurol.2012.10.005

M3 - Article

VL - 239

SP - 192

EP - 201

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -